{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:30:23Z","timestamp":1794641423961,"version":"4.9.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01730-8","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T21:36:05Z","timestamp":1748036165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowri","family":"Sivaramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"1730_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrendo.2018.24","volume":"14","author":"HF Escobar-Morreale","year":"2018","unstructured":"Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14:270\u201384.","journal-title":"Nat Rev Endocrinol"},{"key":"1730_CR2","unstructured":"Polycystic ovary syndrome. World Health Organization. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/polycystic-ovary-syndrome#:~:text=PCOS%20can%20cause%20hormonal%20imbalances,condition%20and%20cannot%20be%20cured. Accessed on Feb 8 2025."},{"key":"1730_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2337\/diaspect.28.2.116","volume":"28","author":"CC Dennett","year":"2015","unstructured":"Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment. Diabetes Spectr. 2015;28:116\u201320.","journal-title":"Diabetes Spectr"},{"key":"1730_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0301-2115(99)00287-0","volume":"91","author":"ES Sills","year":"2000","unstructured":"Sills ES, Perloe M, Palermo GD. Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Eur J Obstet Gynecol Reprod Biol. 2000;91:135\u201341.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1730_CR5","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3390\/jcm12041454","volume":"12","author":"S Singh","year":"2023","unstructured":"Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12:1454.","journal-title":"J Clin Med"},{"key":"1730_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.18773\/austprescr.2024.030","volume":"47","author":"C Ee","year":"2024","unstructured":"Ee C, Tay CT. Pharmacological management of polycystic ovary syndrome. Aust Prescr. 2024;47:109\u201312.","journal-title":"Aust Prescr"},{"key":"1730_CR7","doi-asserted-by":"publisher","first-page":"204201882093830","DOI":"10.1177\/2042018820938305","volume":"11","author":"MA Abdalla","year":"2020","unstructured":"Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020;11:2042018820938305.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1730_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:234.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1730_CR9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/ph16060836","volume":"16","author":"S Pandey","year":"2023","unstructured":"Pandey S, Mangmool S, Parichatikanond W. Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective. Pharmaceuticals. 2023;16(6):836. https:\/\/doi.org\/10.3390\/ph16060836.","journal-title":"Pharmaceuticals"},{"key":"1730_CR10","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/jcm12082824","volume":"12","author":"A Rastogi","year":"2023","unstructured":"Rastogi A, Januzzi JL Jr. Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors in cardiovascular disease and chronic kidney disease. J Clin Med. 2023;12:2824.","journal-title":"J Clin Med"},{"key":"1730_CR11","doi-asserted-by":"publisher","first-page":"1086672","DOI":"10.3389\/fcvm.2022.1086672","volume":"9","author":"TW Kao","year":"2022","unstructured":"Kao TW, Huang CC. Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. Front Cardiovasc Med. 2022;9:1086672.","journal-title":"Front Cardiovasc Med"},{"key":"1730_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1645","volume":"386","author":"E Mahase","year":"2024","unstructured":"Mahase E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024;386: q1645.","journal-title":"BMJ"},{"key":"1730_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023811","volume":"11","author":"R Adhikari","year":"2022","unstructured":"Adhikari R, Jha K, Dardari Z, Heyward J, Blumenthal RS, Eckel RH, Alexander GC, Blaha MJ. National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. 2022;11: e023811.","journal-title":"J Am Heart Assoc"},{"key":"1730_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/biomedicines11040998","volume":"11","author":"D Rakic","year":"2023","unstructured":"Rakic D, Jakovljevic V, Jovic N, Bicanin Ilic M, Dimitrijevic A, Vulovic T, Arsenijevic P, Sretenovic J, Nikolic M, Petrovich Fisenko V, et al. The Potential of SGLT-2 inhibitors in the treatment of polycystic ovary syndrome: the current status and future perspectives. Biomedicines. 2023;11:998.","journal-title":"Biomedicines"},{"issue":"12","key":"1730_CR15","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.3390\/jcm12185915","volume":"12","author":"A Szczesnowicz","year":"2023","unstructured":"Szczesnowicz A, Szeliga A, Niwczyk O, Bala G, Meczekalski B. Do GLP-1 analogs have a place in the treatment of pcos? new insights and promising therapies. J Clin Med. 2023;12(12):5915.","journal-title":"J Clin Med"},{"key":"1730_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.830401","volume":"13","author":"B Sinha","year":"2022","unstructured":"Sinha B, Ghosal S. A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors on metabolic parameters in patients with polycystic ovary syndrome. Front Endocrinol. 2022;13: 830401.","journal-title":"Front Endocrinol"},{"key":"1730_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","volume":"23","author":"L Zhou","year":"2023","unstructured":"Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord. 2023;23:245.","journal-title":"BMC Endocr Disord"},{"key":"1730_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40618-021-01666-6","volume":"45","author":"JJ Ge","year":"2022","unstructured":"Ge JJ, Wang DJ, Song W, Shen SM, Ge WH. The effectiveness and safety of liraglutide in treating overweight\/obese patients with polycystic ovary syndrome: a meta-analysis. J Endocrinol Invest. 2022;45:261\u201373.","journal-title":"J Endocrinol Invest"},{"key":"1730_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12:103\u201311.","journal-title":"Intern Emerg Med"},{"key":"1730_CR20","unstructured":"Open Science Framework. https:\/\/osf.io\/bgmah. Accessed on 9th Jan 2025."},{"key":"1730_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\u00e1-L\u00f3pez F, G\u00f8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"1730_CR22","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928","DOI":"10.1136\/bmj.d5928"},{"issue":"14","key":"1730_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"19","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;19(14):135.","journal-title":"BMC Med Res Methodol"},{"key":"1730_CR24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"1730_CR25","unstructured":"EpiGear International. https:\/\/www.epigear.com\/index.htm. Accessed on 6 Jan 2025."},{"key":"1730_CR26","unstructured":"Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/. Accessed on 12 Dec 2024."},{"key":"1730_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/dom.14583","volume":"24","author":"M Cai","year":"2022","unstructured":"Cai M, Shao X, Xing F, Zhang Y, Gao X, Zeng Q, Dilimulati D, Qu S, Zhang M. Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open-label, noninferiority trial. Diabetes Obes Metab. 2022;24:312\u201320.","journal-title":"Diabetes Obes Metab"},{"key":"1730_CR28","doi-asserted-by":"publisher","unstructured":"El Gohary DSE, Ismail MM, El khayat AM, Elbohoty SB. Effect of Empagliflozin Metformin with Clomiphene Citrate versus Metformin with Clomiphene Citrate on cases of Polycystic Ovary Syndrome, J Med Sci Res; 2023. https:\/\/doi.org\/10.59299\/2537-0928.1025.","DOI":"10.59299\/2537-0928.1025"},{"key":"1730_CR29","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1210\/clinem\/dgab408","volume":"106","author":"KE Elkind-Hirsch","year":"2021","unstructured":"Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab. 2021;106:3019\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"1730_CR30","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/cen.13968","volume":"90","author":"Z Javed","year":"2019","unstructured":"Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, Khan AY, Kilpatrick ES, Atkin SL, Sathyapalan T. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clin Endocrinol. 2019;90:805\u201313.","journal-title":"Clin Endocrinol"},{"key":"1730_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1530\/EC-20-0173","volume":"9","author":"Z Javed","year":"2020","unstructured":"Javed Z, Papageorgiou M, Madden LA, Rigby AS, Kilpatrick ES, Atkin SL, Sathyapalan T. The effects of empagliflozin vs metformin on endothelial microparticles in overweight\/obese women with polycystic ovary syndrome. Endocr Connect. 2020;9:563\u20139.","journal-title":"Endocr Connect"},{"key":"1730_CR32","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/dom.14495","volume":"23","author":"S Tan","year":"2021","unstructured":"Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D, Dunschen K, Zakaria M, Huseinovic N, Basson CT, Mahling P, Fuhrer D, Hinder M. Licogliflozin versus placebo in women with polycystic ovary syndrome: a randomized, double-blind, phase 2 trial. Diabetes Obes Metab. 2021;23:2595\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1730_CR33","doi-asserted-by":"publisher","first-page":"1003238","DOI":"10.3389\/fendo.2022.1003238","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Xing C, Cheng X, He B. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. Front Endocrinol. 2022;13:1003238.","journal-title":"Front Endocrinol"},{"key":"1730_CR34","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:2670\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1730_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","volume":"118","author":"KE Elkind-Hirsch","year":"2022","unstructured":"Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022;118:371\u201381.","journal-title":"Fertil Steril"},{"key":"1730_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.13053","volume":"20","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, Skouby SO, Faber J. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab. 2018;20:215\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1730_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/EC-17-0327","volume":"7","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing S, Nylander M, Kistorp C, Skouby SO, Faber J. Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Endocr Connect. 2018;7:115\u201323.","journal-title":"Endocr Connect"},{"key":"1730_CR38","doi-asserted-by":"publisher","first-page":"4288004","DOI":"10.1155\/2023\/4288004","volume":"2023","author":"J Gan","year":"2023","unstructured":"Gan J, Chen J, Ma RL, Deng Y, Ding XS, Zhu SY, Sun AJ. Action mechanisms of metformin combined with exenatide and metformin only in the treatment of PCOS in obese patients. Int J Endocrinol. 2023;2023:4288004.","journal-title":"Int J Endocrinol"},{"key":"1730_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF03401383","volume":"14","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones. 2015;14:81\u201390.","journal-title":"Hormones"},{"key":"1730_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13048-015-0161-3","volume":"8","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015;8:32.","journal-title":"J Ovarian Res"},{"key":"1730_CR41","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3892\/etm.2016.3081","volume":"11","author":"M Jensterle","year":"2016","unstructured":"Jensterle M, Goricar K, Janez A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study. Exp Ther Med. 2016;11:1194\u2013200.","journal-title":"Exp Ther Med"},{"key":"1730_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12902-017-0155-9","volume":"17","author":"M Jensterle","year":"2017","unstructured":"Jensterle M, Kravos NA, Gori\u010dar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord. 2017;17:5.","journal-title":"BMC Endocr Disord"},{"key":"1730_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108935","volume":"178","author":"M Jensterle","year":"2021","unstructured":"Jensterle M, Ferjan S, Vovk A, Battelino T, Rizzo M, Jane\u017e A. Semaglutide reduces fat accumulation in the tongue: a randomized single-blind, pilot study. Diabetes Res Clin Pract. 2021;178: 108935.","journal-title":"Diabetes Res Clin Pract"},{"key":"1730_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/dom.14944","volume":"25","author":"M Jensterle","year":"2023","unstructured":"Jensterle M, Ferjan S, Le\u017eai\u010d L, So\u010dan A, Gori\u010dar K, Zaletel K, Janez A. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. 2023;25:975\u201384.","journal-title":"Diabetes Obes Metab"},{"key":"1730_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12020-023-03487-4","volume":"83","author":"M Liao","year":"2024","unstructured":"Liao M, Li X, Zhang H, Zhou L, Shi L, Li W, Shen R, Peng G, Zhao H, Shao J, Wang X, Sun Z, Zheng H, Long M. Effects and plasma proteomic analysis of GLP-1RA versus CPA\/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Endocrine. 2024;83:227\u201341.","journal-title":"Endocrine"},{"key":"1730_CR46","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/cen.13454","volume":"87","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Zheng SY, Lin R, Xie YJ, Chen H, Zheng YX, Liu E, Chen L, Yan JH, Xu W, Mai TT, Gong Y. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin Endocrinol. 2017;87:767\u201374.","journal-title":"Clin Endocrinol"},{"key":"1730_CR47","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1097\/CM9.0000000000001712","volume":"134","author":"RL Ma","year":"2021","unstructured":"Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ. Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome. Chin Med J. 2021;134:2882\u20139.","journal-title":"Chin Med J"},{"key":"1730_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","volume":"35","author":"M Nylander","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35:121\u20137.","journal-title":"Reprod Biomed Online"},{"key":"1730_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EC-16-0113","volume":"6","author":"M Nylander","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Kistorp C, Faber J, Skouby SO. Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocr Connect. 2017;6:89\u201399.","journal-title":"Endocr Connect"},{"key":"1730_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Vrtacnik BE. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179:1\u201311.","journal-title":"Eur J Endocrinol"},{"key":"1730_CR51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170:451\u20139.","journal-title":"Eur J Endocrinol"},{"key":"1730_CR52","doi-asserted-by":"publisher","first-page":"e1420","DOI":"10.1210\/clinem\/dgaa692","volume":"106","author":"T Tao","year":"2021","unstructured":"Tao T, Zhang Y, Zhu YC, Fu JR, Wang YY, Cai J, Ma JY, Xu Y, Gao YN, Sun Y, Fan W, Liu W. Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study. J Clin Endocrinol Metab. 2021;106:e1420\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"1730_CR53","first-page":"8406","volume":"28","author":"J Wang","year":"2017","unstructured":"Wang J, Ruan X, Jin F, Sun Y, Wang J. Effects of exenatide combined with clomifene citrate on insulin resistance and angiotensin II\/angiotensin-(1\u20137) in peripheral blood in patients with polycystic ovary syndrome. Biomed Res. 2017;28:8406\u201311.","journal-title":"Biomed Res"},{"key":"1730_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.945609","volume":"13","author":"C Xing","year":"2022","unstructured":"Xing C, Zhao H, Zhang J, He B. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front Endocrinol. 2022;13: 945609.","journal-title":"Front Endocrinol"},{"key":"1730_CR55","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/nu15030556","volume":"15","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qu Z, Lu T, Shao X, Cai M, Dilimulati D, Gao X, Mao W, Hu F, Su L, Liao Q, Han T, Zhang M, Qu S. Effects of a dulaglutide plus calorie-restricted diet versus a calorie-restricted diet on visceral fat and metabolic profiles in women with polycystic ovary syndrome: a randomized controlled trial. Nutrients. 2023;15:556.","journal-title":"Nutrients"},{"key":"1730_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.obmed.2017.06.003","volume":"7","author":"S Zheng","year":"2017","unstructured":"Zheng S, Zhang Y, Long T, Lu J, Liu X, Yan J, Chen L, Gong Y, Wang F. Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight\/obese PCOS women. Obesity Medicine. 2017;7:15\u201320.","journal-title":"Obesity Medicine"},{"key":"1730_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126119","volume":"10","author":"V Hoang","year":"2015","unstructured":"Hoang V, Bi J, Mohankumar SM, Vyas AK. Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome. PLoS ONE. 2015;10: e0126119.","journal-title":"PLoS ONE"},{"key":"1730_CR58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5937\/afmnai2001034K","volume":"37","author":"B Koksal","year":"2020","unstructured":"Koksal B, Yildiz S, Ozgocer T, Yildiz A, Vardi N, Barutcu O. Investigation of possible effects of exendin-4 during exposure to mild chronic stress on dehydroepiandrosterone-induced polycystic ovary syndrome in rats. Acta facultatis medicae Naissensis. 2020;37:34\u201347.","journal-title":"Acta facultatis medicae Naissensis"},{"key":"1730_CR59","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.2147\/DDDT.S484531","volume":"18","author":"M Liu","year":"2024","unstructured":"Liu M, Guo S, Li X, Tian Y, Yu Y, Tang L, Sun Q, Zhang T, Fan M, Zhang L, Xu Y, An J, Gao X, Han L, Zhang L. Semaglutide alleviates ovary inflammation via the AMPK\/SIRT1\/NF-\u03baB signaling pathway in polycystic ovary syndrome mice. Drug Des Devel Ther. 2024;18:3925\u201338.","journal-title":"Drug Des Devel Ther"},{"key":"1730_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118731","volume":"265","author":"MA Saad","year":"2021","unstructured":"Saad MA, Eltarzy MA, Abdel Salam RM, Ahmed MAE. Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome. Life Sci. 2021;265: 118731.","journal-title":"Life Sci"},{"key":"1730_CR61","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12020-019-01891-3","volume":"64","author":"A Singh","year":"2019","unstructured":"Singh A, Fernandes JRD, Chhabra G, Krishna A, Banerjee A. Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice. Endocrine. 2019;64:349\u201366.","journal-title":"Endocrine"},{"key":"1730_CR62","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1177\/1933719116635278","volume":"23","author":"L Sun","year":"2016","unstructured":"Sun L, Ji C, Jin L, Bi Y, Feng W, Li P, Shen S, Zhu D. Effects of exenatide on metabolic changes, sexual hormones, inflammatory cytokines, adipokines, and weight change in a DHEA-treated rat model. Reprod Sci. 2016;23:1242\u20139.","journal-title":"Reprod Sci"},{"key":"1730_CR63","unstructured":"Tao X, Zhang X, Ge S-Q, Zhang Er-H, Zhang B. Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. Int J Clin Exp Pathol 2015; 8: 8276\u20138283."},{"key":"1730_CR64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13048-019-0555-8","volume":"12","author":"X Tao","year":"2019","unstructured":"Tao X, Cai L, Chen L, Ge S, Deng X. Effects of metformin and Exenatide on insulin resistance and AMPK\u03b1-SIRT1 molecular pathway in PCOS rats. J Ovarian Res. 2019;12:86.","journal-title":"J Ovarian Res"},{"key":"1730_CR65","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1210\/en.2019-00450","volume":"160","author":"ED Torres Fernandez","year":"2019","unstructured":"Torres Fernandez ED, Huffman AM, Syed M, Romero DG, Yanes Cardozo LL. Effect of GLP-1 receptor agonists in the cardiometabolic complications in a rat model of postmenopausal PCOS. Endocrinology. 2019;160:2787\u201399.","journal-title":"Endocrinology"},{"key":"1730_CR66","doi-asserted-by":"publisher","DOI":"10.5653\/cerm.2024.06912","author":"A Vatankhah","year":"2024","unstructured":"Vatankhah A, Jamhiri M, Vatankhah S, Lorian K, Rezvani ME, Izadi M. Improved ovarian adiponectin system expression in polycystic ovary syndrome treated with exenatide. Clin Exp Reprod Med. 2024. https:\/\/doi.org\/10.5653\/cerm.2024.06912.","journal-title":"Clin Exp Reprod Med"},{"key":"1730_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2021.170624","volume":"145","author":"LM Wu","year":"2021","unstructured":"Wu LM, Wang YX, Zhan Y, Liu AH, Wang YX, Shen HF, Wang YF, Wang LY, Tao ZB, Wang YQ. Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats. Peptides. 2021;145: 170624.","journal-title":"Peptides"},{"key":"1730_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2021.105992","volume":"214","author":"C Xing","year":"2021","unstructured":"Xing C, Lv B, Zhao H, Wang D, Li X, He B. Metformin and exenatide upregulate hepatocyte nuclear factor-4\u03b1, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats. J Steroid Biochem Mol Biol. 2021;214: 105992.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1730_CR69","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2147\/DMSO.S451129","volume":"17","author":"C Xiong","year":"2024","unstructured":"Xiong C, Wu J, Ma Y, Li N, Wang X, Li Y, Ding X. Effects of glucagon-like peptide-1 receptor agonists on gut microbiota in dehydroepiandrosterone-induced polycystic ovary syndrome mice: compared evaluation of liraglutide and semaglutide intervention. Diabetes Metab Syndr Obes. 2024;17:865\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1730_CR70","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/biolre\/ioad032","volume":"108","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Lin Y, Li G, Yuan Y, Wang X, Li N, Xiong C, Yang Y, Ma Y, Zhang Z, Ding X. Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue\u2020. Biol Reprod. 2023;108:945\u201359.","journal-title":"Biol Reprod"},{"key":"1730_CR71","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/09513590.2022.2109144","volume":"38","author":"X Yuan","year":"2022","unstructured":"Yuan X, Huang Q, Li J, Yao Q, Zhang H, Wang Q, Zhang L, Zhang Y, Yang G, Li L, Liao X. Bone morphogenetic protein-9 maybe an important factor which improves insulin resistance in PCOS. Gynecol Endocrinol. 2022;38:781\u20139.","journal-title":"Gynecol Endocrinol"},{"key":"1730_CR72","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15858","volume":"11","author":"MM Mahmoud","year":"2023","unstructured":"Mahmoud MM, Rashed LA, Soliman SA, Sayed SM, Kamel O, Kamar SS, Hussien RES. SGLT-2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model. Physiol Rep. 2023;11: e15858.","journal-title":"Physiol Rep"},{"key":"1730_CR73","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/pathophysiology31040041","volume":"31","author":"D Rakic","year":"2024","unstructured":"Rakic D, Jakovljevic V, Zivkovic V, Jakovljevic Uzelac J, Jovic N, Muric M, Pindovic B, Dimitrijevic A, Arsenijevic P, Rakic J, Mitrovic S, Vulovic T, Joksimovic JJ. Multiple benefits of empagliflozin in pcos: evidence from a preclinical rat model. Pathophysiology. 2024;31:559\u201382.","journal-title":"Pathophysiology"},{"key":"1730_CR74","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s43032-024-01503-0","volume":"31","author":"S Ji","year":"2024","unstructured":"Ji S, Yang H, Ji Y, Wu W, Dong Y, Fu H, Tang N, Hou Z, Wang F. Liraglutide improves PCOS symptoms in rats by targeting FDX1. Reprod Sci. 2024;31:2049\u201358.","journal-title":"Reprod Sci"},{"key":"1730_CR75","doi-asserted-by":"publisher","first-page":"100","DOI":"10.30827\/ars.v64i2.27302","volume":"64","author":"S Kesavan","year":"2023","unstructured":"Kesavan S, Akim AM, Chaudry G, Ranneh YK. The efficacy of metformin and exenatide in polycystic ovary syndrome (PCOS) patients. Ars Pharm. 2023;64:100\u201322.","journal-title":"Ars Pharm"},{"key":"1730_CR76","doi-asserted-by":"crossref","unstructured":"Austreg\u00e9silo de Athayde De Hollanda Morais B, Martins Priz\u00e3o V, de Moura de Souza M, Ximenes Mendes B, Rodrigues Defante ML, Cosendey Martins O, Rodrigues AM. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. J Diabetes Complications. 2024; 38: 108834.","DOI":"10.1016\/j.jdiacomp.2024.108834"},{"key":"1730_CR77","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1007\/s43032-023-01222-y","volume":"30","author":"ZR Ye","year":"2023","unstructured":"Ye ZR, Yan CQ, Liao N, Wen SH. The effectiveness and safety of exenatide versus metformin in patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Reprod Sci. 2023;30:2349\u201361.","journal-title":"Reprod Sci"},{"key":"1730_CR78","first-page":"1","volume":"21","author":"ABM Kamrul-Hasan","year":"2025","unstructured":"Kamrul-Hasan ABM, Mondal S, Aalpona FTZ, Nagendra L, Dutta D. Role of sodium-glucose cotransporter-2 inhibitors in managing polycystic ovary syndrome: a systematic review. Touch Rev Endocrinol. 2025;21:1.","journal-title":"Touch Rev Endocrinol"},{"key":"1730_CR79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12958-023-01075-9","volume":"21","author":"G Peng","year":"2023","unstructured":"Peng G, Yan Z, Liu Y, Li J, Ma J, Tong N, Wang Y. The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2023;21:24.","journal-title":"Reprod Biol Endocrinol"},{"key":"1730_CR80","first-page":"675","volume":"105","author":"MJ Arnold","year":"2022","unstructured":"Arnold MJ, Buelt A. SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes: BMJ rapid recommendation. Am Fam Physician. 2022;105:675\u20137.","journal-title":"Am Fam Physician"},{"key":"1730_CR81","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398:262\u201376.","journal-title":"Lancet"},{"key":"1730_CR82","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033572","volume":"13","author":"CT Tay","year":"2024","unstructured":"Tay CT, Mousa A, Vyas A, Pattuwage L, Tehrani FR, Teede H. 2023 international evidence-based polycystic ovary syndrome guideline update: insights from a systematic review and meta-analysis on elevated clinical cardiovascular disease in polycystic ovary syndrome. J Am Heart Assoc. 2024;13: e033572.","journal-title":"J Am Heart Assoc"},{"key":"1730_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242","volume":"385","author":"N Simms-Williams","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, Renoux C, Suissa S, Azoulay L. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024;385: e078242.","journal-title":"BMJ"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01730-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T23:40:45Z","timestamp":1748043645000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01730-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1730"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01730-8","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}